British Dietetic Association systematic review of systematic reviews and evidence‐based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update)
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background: Probiotics are often taken by individuals with irritable bowel syndrome (IBS). Which products are effective is unclear, despite an increasing research base. This project will systematically review which strain‐ and dose‐ specific probiotics can be recommended to adults with IBS to improve symptoms and quality of life (QoL). It is part of a broader systematic review to update British Dietetic Association guidelines for the dietary management of IBS in adults. Methods: CINAHL, Cochrane, Embase, Medline, Scopus and Web of Science were searched for systematic reviews (SR s) of randomised controlled trial (RCT)s recruiting adults with IBS comparing probiotic intervention with placebo. AMSTAR, risk of bias and diet bias tools were used to appraise methodological quality. Symptom and QoL data were appraised to develop probiotic‐specific evidence statements on clinically meaningful and marginal outcomes in various settings, graded clinical practice recommendations and practical considerations. Results: Nine systematic reviews and 35 RCT s were included (3406 participants) using 29 dose‐specific probiotic formulations. None of the RCT s were at low risk of bias. Twelve out of 29 probiotics (41%) showed no symptom or QoL benefits. Evidence indicated that no strain or dose specific probiotic was consistently effective to improve any IBS symptoms or QoL. Two general clinical practice recommendations were made. Conclusions: Symptom outcomes for dose‐specific probiotics were heterogeneous. Specific probiotic recommendations for IBS management in adults were not possible at this time. More data from high‐quality RCT s treating specific symptom profiles are needed to support probiotic therapy in the management of IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., Moher, D., & Bouter, L. M. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-10 · Cited by 4,374
The functional gastrointestinal disorders and the Rome III process
Drossman, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.008 · Cited by 2,416
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome
Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.046 · Cited by 1,249
Methodology in conducting a systematic review of systematic reviews of healthcare interventions
Smith, V., Devane, D., Begley, C. M., & Clarke, M. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-15 · Cited by 1,227
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939 · cited 1×
“Alterations in the colonic microbiota in IBS may explain a reduction in antiinflammatory cytokine levels (interleukin-10) (45) and visceral hypersensitivity ((87)), increasing IBS symptoms ((85)).”
BackgroundFord, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747 · cited 4×
“NNT and NNH) is useful; however, the data were limited and so future studies should be designed to easily measure these by including a binary yes/no clinical response endpoint for adequate relief of symptoms ((31)).”
BackgroundMethodInfluentialThe efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010) · Gut · doi:10.1136/gut.2008.167270 · Cited by 728 · cited 2×
“Considering how IBS symptoms fluctuate over time, there may be a net benefit for some individuals to trial a probiotic because there is a high placebo response ((26)).”
BackgroundStaudacher, H. M., Lomer, M. C. E., Anderson, J. L., Barrett, J. S., Muir, J. G., Irving, P. M., & Whelan, K. (2012) · The Journal of Nutrition · doi:10.3945/jn.112.159285 · Cited by 590 · cited 1×
“dietary fibre and FODMAPs) influence IBS symptoms (11,83–86) and the colonic microbiota ((83,84)).”
BackgroundSelf-citationNiedzielin, K., Kordecki, H., & Birkenfeld, B. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200110000-00004 · Cited by 506
Kim, H. J., Camilleri, M., Mckinzie, S., Lempke, M. B., Burton, D. D., Thomforde, G. M., & Zinsmeister, A. R. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01543.x · Cited by 468
Review article: the economic impact of the irritable bowel syndrome
Canavan, C., West, J., & Card, T. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12938 · Cited by 458 · cited 1×
“There is increasing recognition that measurement of quality of life (QoL) in RCTs is important, considering the debilitating burden that IBS places on individuals, with associated high healthcare and socio-economic costs ((9,10)).”
BackgroundFurther validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424
Kim, H. J., Vazquez Roque, M. I., Camilleri, M., Stephens, D., Burton, D. D., Baxter, K., Thomforde, G., & Zinsmeister, A. R. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00695.x · Cited by 400 · cited 6×
“8-strainx (9x1011) powder Kim 2005(60) IBS with bloating Rome II USA secondary care 48 24 24 0 4w 2w NS Rome II secondary care NS 4-strainp (4x109) capsule Jafari 2014(57) IBS with bloating Iran 108 54 54 0w 4w 4w 3-straino (5x107) fermented milk Simren 2010(64) IBS-D,C,M Rome II Sweden secondary care 74 37 37 2w 8w 8…”
BackgroundInfluentialKAJANDER, K., MYLLYLUOMA, E., RAJILIĆ‐STOJANOVIĆ, M., KYRÖNPALO, S., RASMUSSEN, M., JÄRVENPÄÄ, S., ZOETENDAL, E. G., DE VOS, W. M., VAPAATALO, H., & KORPELA, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03542.x · Cited by 367
GUYONNET, D., CHASSANY, O., DUCROTTE, P., PICARD, C., MOURET, M., MERCIER, C. ‐., & MATUCHANSKY, C. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03362.x · Cited by 365
Monsbakken, K. W., Vandvik, P. O., & Farup, P. G. (2006) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602367 · Cited by 364
The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review
Brenner, D. M., Moeller, M. J., Chey, W. D., & Schoenfeld, P. S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.25 · Cited by 362
KAJANDER, K., HATAKKA, K., POUSSA, T., FÄRKKILÄ, M., & KORPELA, R. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02579.x · Cited by 361
Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena?
Rajilić-Stojanović, M., Jonkers, D. M., Salonen, A., Hanevik, K., Raes, J., Jalanka, J., de Vos, W. M., Manichanh, C., Golic, N., Enck, P., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.427 · Cited by 359
Meta-analysis of probiotics for the treatment of irritable bowel syndrome
McFarland, L. V., & Dublin, S. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2650 · Cited by 341
AGRAWAL, A., HOUGHTON, L. A., MORRIS, J., REILLY, B., GUYONNET, D., GOUPIL FEUILLERAT, N., SCHLUMBERGER, A., JAKOB, S., & WHORWELL, P. J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03853.x · Cited by 334 · cited 10×
“Fourteen RCTs showed statistically significant improvements for adequate symptom relief (38,39,42,54,57,58,68), a VAS (45,49,50,55,56) or the IBS-SSS (65,67).”
BackgroundMethodInfluentialA systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome
Hoveyda, N., Heneghan, C., Mahtani, K. R., Perera, R., Roberts, N., & Glasziou, P. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-15 · Cited by 297 · cited 1×
“It has been argued that meta-analysis may be superior to systematic review in the assessment of probiotic RCTs in IBS management ((25,27,30,31,33)).”
BackgroundGuglielmetti, S., Mora, D., Gschwender, M., & Popp, K. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04633.x · Cited by 287 · cited 1×
“Three of these studies had 86 ((92)), 103 (91) and 122 (90) participants each where medication was allowed throughout the intervention for constipation and diarrhoea (90–92) and, additionally, abdominal pain and flatulence ((91,92)).”
BackgroundDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Whitehead, W. E., Chey, W. D., Matsueda, K., Shaw, M., Talley, N. J., & Veldhuyzen van Zanten, S. J. O. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.058 · Cited by 286
Sen, S., Mullan, M. M., Parker, T. J., Woolner, J. T., Tarry, S. A., & Hunter, J. O. (2002) · Digestive Diseases and Sciences · doi:10.1023/a:1020597001460 · Cited by 245 · cited 1×
“The other systematic review was published by a European expert consensus group and was based on primary outcomes for each RCT ((29)); however, over half of the included RCTs were in secondary care and included studies with less than 20 participants ((73,74)).”
BackgroundKi Cha, B., Mun Jung, S., Hwan Choi, C., Song, I.-D., Woong Lee, H., Joon Kim, H., Hyuk, J., Kyung Chang, S., Kim, K., Chung, W.-S., et al. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31823712b1 · Cited by 216 · cited 25×
“Clinically meaningful improvements were found using two probiotics, one with two different doses, a threestrain probiotic: L. plantarum CECT7484 and CECT7485 and Pediococcus acidilactici CECT7483 taken at a daily dose of 3.6 9 109 and 1 9 1010 for 6 weeks in IBS-D patients (62), and a four-strain probiotic: B. bifidum…”
BackgroundMethodInfluentialHungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.-M., Rubin, G., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12460 · Cited by 212 · cited 2×
“Nine systematic reviews met the inclusion criteria (25–33) and were appraised (see Supporting information, Tables S4 and S5); six reviewed probiotic treatment for IBS (25–28,30,32) and one for lower gastrointestinal symptoms ((29)), one reviewed probiotics, prebiotics and synbiotics in IBS (33) and another in IBS and…”
BackgroundNIV, E., NAFTALI, T., HALLAK, R., & VAISMAN, N. (2005) · Clinical Nutrition · doi:10.1016/j.clnu.2005.06.001 · Cited by 191
Validation of a specific quality of life questionnaire for functional digestive disorders
Chassany, O., Marquis, P., Scherrer, B., Read, N. W., Finger, T., Bergmann, J. F., Fraitag, B., Geneve, J., & Caulin, C. (1999) · Gut · doi:10.1136/gut.44.4.527 · Cited by 180
SIMRÉN, M., ÖHMAN, L., OLSSON, J., SVENSSON, U., OHLSON, K., POSSERUD, I., & STRID, H. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04183.x · Cited by 169 · cited 10×
“8-strainx (9x1011) powder Kim 2005(60) IBS with bloating Rome II USA secondary care 48 24 24 0 4w 2w NS Rome II secondary care NS 4-strainp (4x109) capsule Jafari 2014(57) IBS with bloating Iran 108 54 54 0w 4w 4w 3-straino (5x107) fermented milk Simren 2010(64) IBS-D,C,M Rome II Sweden secondary care 74 37 37 2w 8w 8…”
BackgroundMethodResultInfluentialSinn, D. H., Song, J. H., Kim, H. J., Lee, J. H., Son, H. J., Chang, D. K., Kim, Y.-H., Kim, J. J., Rhee, J. C., & Rhee, P.-L. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0196-4 · Cited by 163
WILLIAMS, E. A., STIMPSON, J., WANG, D., PLUMMER, S., GARAIOVA, I., BARKER, M. E., & CORFE, B. M. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03848.x · Cited by 156 · cited 8×
“Reference RCT risk of bias(22) Dietary risk of bias Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Agrawal 2009 (50) ? ? + + + - - + + ? ? ? ? Begtrup 2013(53) ? ? + + - + - + + ? ? ? ? Charbonneau 2013 (35) ? ? + + + + - + ? ? ? + ? Choi 2011 (36) + + + + - - - + ? ? + ? ? Dolin 2009(37) ? ? + ? + - - + ? + ? ? ? Ducrott…”
BackgroundInfluentialSisson, G., Ayis, S., Sherwood, R. A., & Bjarnason, I. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12787 · Cited by 147 · cited 14×
“Fourteen RCTs showed statistically significant improvements for adequate symptom relief (38,39,42,54,57,58,68), a VAS (45,49,50,55,56) or the IBS-SSS (65,67).”
BackgroundMethodInfluentialChoi, C. H., Jo, S. Y., Park, H. J., Chang, S. K., Byeon, J.-S., & Myung, S.-J. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318204593e · Cited by 144 · cited 17×
“In IBS-D, global symptom improvement was seen with a seven-strain probiotic: L. acidophilus, L. plantarum, L. rhamnosus, B. breve, B. lactis, B. longum and S. thermophilus (58) and a four-strain probiotic: B. bifidum IBS-C significant in subtype IBS-C, IBS-D significant in subtype IBS-D, IBS-M significant in IBS-M, +I…”
BackgroundMethodInfluentialLigaarden, S. C., Axelsson, L., Naterstad, K., Lydersen, S., & Farup, P. G. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-16 · Cited by 103
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis
Ortiz-Lucas, M., Aurelio, T., Saz, P., & Sebastián, J. J. (2013) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082013000100005 · Cited by 103
Charbonneau, D., Gibb, R. D., & Quigley, E. M. M. (2013) · Gut Microbes · doi:10.4161/gmic.24196 · Cited by 99 · cited 4×
“Evidence is lacking to show any symptom or QoL improvements after the use of 12/29 (41%) dose-specific probiotics: Bifidobacterium infantis 35264 at a dose of 1 9 10(6) CFU and 1 9 10(10) CFU 1 capsule per day for 4 weeks in primary care (49) and at dose 1 9 10(9) 1 capsule per day for 8 weeks (unclear setting) (35) E…”
BackgroundInfluentialSøndergaard, B., Olsson, J., Ohlson, K., Svensson, U., Bytzer, P., & Ekesbo, R. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.565066 · Cited by 84
Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome
Hong, K. S., Kang, H. W., Im, J. P., Ji, G. E., Kim, S. G., Jung, H. C., Song, I. S., & Kim, J. S. (2009) · Gut and Liver · doi:10.5009/gnl.2009.3.2.101 · Cited by 75
Cited by
The pros, cons, and many unknowns of probiotics
Suez, J., Zmora, N., Segal, E., & Elinav, E. (2019) · Nature Medicine · doi:10.1038/s41591-019-0439-x · Cited by 1,398
The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS
Staudacher, H. M., & Whelan, K. (2017) · Gut · doi:10.1136/gutjnl-2017-313750 · Cited by 387
McKenzie, Y. A., Bowyer, R. K., Leach, H., Gulia, P., Horobin, J., O'Sullivan, N. A., Pettitt, C., Reeves, L. B., Seamark, L., Williams, M., et al. (2016) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12385 · Cited by 353
Self-citationWhelan, K., Martin, L. D., Staudacher, H. M., & Lomer, M. C. E. (2018) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12530 · Cited by 290
Self-citationRossi, M., Aggio, R., Staudacher, H. M., Lomer, M. C., Lindsay, J. O., Irving, P., Probert, C., & Whelan, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.09.055 · Cited by 122
Self-citation
Metadata
- Authors
- McKenzie, Y. A., Thompson, J., Gulia, P., Lomer, M. C. E., & (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association)
- Venue
- Journal of Human Nutrition and Dietetics
- Publisher
- Wiley
- Published
- 2016-06-06
- Volume
- 29
- Issue
- 5
- Pages
- 576-592
- ISSN
- 0952-3871 (ISSN-L)
- 1365-277X
- OpenAlex
- W2416358706
- Cited by
- 80
- References
- 44
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.